

As provided under Section 601 of the Economy Act of 1932, amended 31 U.S.C. 1525, the General Services Administration, through its Agency Liaison Division, provides various personnel management services to a number of diverse Presidential commissions, committees, boards and other agencies through reimbursable administrative support agreements. This notice is processed on behalf of the client agencies, and it supersedes all other notices in the **Federal Register** on this subject. Because of their small size, a Performance Review Board register has been reestablished in which SES members from the client agencies participate. The Board is composed of SES members from various agencies. From this register of names, the head of each client agency will appoint executives to a specific board to serve a particular client agency.

The members whose names appear on the Performance Review Board standing roster to serve client agencies are:

*Barry M. Goldwater Scholarship and Excellence In Education Foundation*

Gerald J. Smith, Executive Secretary

*Committee for Purchase From People Who Are Blind or Severely Disabled*

Leon A. Wilson, Jr., Executive Director

*Federal Retirement Thrift Investment Board*

David L. Black, Director of Accounting  
Lawrence E. Stiffler, Director of  
Automated Systems

Veda R. Charrow, Director of  
Communications

Thomas J. Trabucco, Director of External  
Affairs

James B. Petrick, Director of Benefits  
and Investment

Elizabeth S. Woodruff, General Counsel

Pamela J. Moran, Deputy Director of  
External Affairs

*Harry S. Truman Scholarship  
Foundation*

Louis H. Blair, Executive Secretary

*Japan-United States Friendship  
Commission*

Eric J. Gangloff, Executive Director

*Arctic Research Commission*

Garrett W. Brass, Executive Director

*National Mediation Board*

Benetta M. Mansfield, Chief of Staff

Dated: April 25, 2002.

**Melynda Clarke,**

*Director, Liaison Division.*

[FR Doc. 02-12408 Filed 5-16-02; 8:25 am]

BILLING CODE 6820-34-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

*Aaron J. Morrow, B.S., Saint Louis University:* Based on Mr. Morrow's admission, the report of an investigation conducted by Saint Louis University (SLU), and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Aaron J. Morrow, graduate student, SLU Graduate School, engaged in scientific misconduct by falsifying and fabricating data in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant 5 R01 GM54428-04, "Elucidation of the mechanisms of *in vitro* Golgi transport."

Specifically PHS found that Mr. Morrow falsified data relating to the study of the mechanisms of protein transport using *in vitro* preparations. From October 1999 through January 2001, he falsified and fabricated data in his research notebook and produced false films and graphs of purported experiments to produce data for his thesis and misrepresent his progress.

Mr. Morrow reported the falsified and fabricated data in: (1) Laboratory group meetings; (2) a poster presentation at the American Society for Cell Biology meeting held in December 2000, and (3) a draft manuscript that he was preparing. Mr. Morrow also provided falsified data to his mentor, who unknowingly included it in a draft of NIGMS, NIH, application 2 R01 GM54428-05A2, "Elucidation of the mechanisms of *in vitro* Golgi transport." Given the extensive nature of Mr. Morrow's data falsification and fabrication, none of his research after July 2000 can be considered reliable. His actions adversely and materially affected the laboratory's ongoing research in protein transport mechanisms by creating uncertainty about all his experimental results, necessitating verification and repetition of experiments, preventing the reporting of results for publication, and preventing the principal investigator from submitting a competitive renewal application for a NIH grant.

Mr. Morrow has entered into a Voluntary Exclusion Agreement in which he has voluntarily agreed for a period of three (3) years:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (*e.g.*, grants and cooperative agreements) of the United States Government as defined in 45 CFR part 76 (Debarment Regulations); and

(2) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

#### FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852. (301) 443-5330.

**Chris B. Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. 02-12361 Filed 5-16-02; 8:45 am]

BILLING CODE 4150-31-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Opportunity To Collaborate in the Evaluation of Topical Microbicides To Reduce Sexual Transmission of Human Immunodeficiency Virus (HIV)

**AGENCY:** Centers for Disease Control and Prevention, Department of Health and Human Services (DHHS).

**ACTION:** Opportunities for collaboration for evaluation of topical microbicides.

The Centers for Disease Control and Prevention (CDC), National Center for HIV, STD, and TB Prevention (NCHSTP), Division of HIV/AIDS Prevention-Surveillance and Epidemiology (DHAP-SE), Epidemiology Branch (EpiBr), announces an opportunity for collaboration to evaluate the safety and preliminary efficacy of topical microbicides designed for vaginal and/or rectal application to reduce HIV transmission. These evaluations will include in-vitro assays, macaque studies, and phase I/phase II trials in women and men.

**SUMMARY:** The Division of HIV/AIDS Prevention-Surveillance and Epidemiology (DHAP-SE) of the National Center of HIV, STD, and TB Prevention (NCHSTP) at the Centers for Disease Control and Prevention (CDC) of the Department of Health and Human